Alan Brochstein - Comments
Independent Analyst
I have worked in the investment industry since 1986 and earned the CFA charter in 1997. I worked for Kidder, Peabody in bonds from 1986-1992 and then First Boston's investment management subsidiary from 1992-1994, both in NYC. I then joined Criterion Investment Management (later acquired by ...more
Latest Comments
OGI: My Favorite Canadian LP
26 days ago
This is a good question and am important topic in my view. The good news is that the acquisition closed last December, so after this upcoming report next month for Q1, which will have a full quarter with Motif compared to a partial revenue quarter last year, the Motif revenue will be fully organic for the last three quarters. In FY25-Q1, Motif contributed just C$$7.8 million of gross revenue. The filings from Q4 indicate that Motif total revenue on a gross basis for FY25-Q1 would have been C$38.9 million, including the 10 weeks prior to the acquisition closing. I am not trying to predict the exact amount from Motif Labs for Q1, but a good guess is C$46.8 million. Thus, the inorganic growth in Q1 of gross revenue will be C$39 million. This works out to 58% for Q1 or about 10% for the year.
In this article: OGI
OGI: My Favorite Canadian LP
26 days ago
Thanks for commenting! I do see a lot of risks, as well as some opportunities. The biggest risk in my view, but not the only one, is Canada tanking, as that is where a lot of its business takes place. The Canadian cannabis market is mature and has been slowing. Cannabis historically has been viewed as like a Consumer Staples product, immune to economic weakness, but that is when it is medical in nature. If the Canadian economy is very weak, it could hurt revenue for OGI.
In this article: OGI
21 to 22 of 22 comments
<<< 1 2 3